ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

エスタゾラム

Estazolam

HCID 3261
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
29975-16-4
標準SMILES
Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2
InChIKey
CDCHDCWJMGXXRH-UHFFFAOYSA-N
分子式
C16H11ClN4
平均分子量
294.74 g/mol
単同位体質量
294.0672241

概要

Estazolam is a triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia. It has a role as an anxiolytic drug, an anticonvulsant and a GABA modulator. It is a triazolobenzodiazepine and a member of triazoles.

名称と識別子

優先名称
Estazolam
IUPAC
8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
現地名
エスタゾラム
英語名
Estazolam
分子式
C16H11ClN4
分子量
294.74

名称と別名

estazolam29975-16-4EurodinProSomEsilganD 40TAEstazolamum8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepineAbbott-47631Estazolam civDTXSID50205728-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
名称をさらに表示
エスタゾラムエスタゾラム (JP17)プロソムタブス8-クロロ-6-フェニル-4H-[1,2,4]トリアゾロ[4,3-a][1,4]ベンゾジアゼピンオイロジンヌクタロンエシルガンヨーロジン12-クロロ-9-フェニル-2,4,5,8-テトラアザトリシクロ[8.4.0.02,6]テトラデカ-1(14),3,5,8,10,12-ヘキサエンソムナトロールユ-ロジンユーロジン8-CHLORO-6-PHENYL-4H-[1,2,4]-TRIAZOLO[4,3-A][1,4]BENZODIAZEPINEu33737Cannocd-40taNemurelJulodin
NSC-29081836S3EQV54C4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepineDTXCID50572CHEBI:48588-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepineNSC290818

物性

構造計算による物性補完中

XLogP
1.7
極性表面積
43.1 Ų
水素結合供与体数
0
水素結合受容体数
3
回転可能結合数
1
重原子数
21
形式電荷
0
複雑度
407

実験および物理化学的性質

Drugs · 5 件

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP4.7
Solubility · 2 件

Practically insoluble (1.5 mg/L)

4.23e-02 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2 件

228-229

228.5 °C

Physical DescriptionSolid
Collision Cross Section168.1 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

物理化学的性質

融点

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 2.3% (1 of 44) of reports.

Warning

H315 (93.2%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

DEA schedule IV controlled substance

4H-1,2,4Triazolo4,3-a1,4benzodiazepine, 8-chloro-6-phenyl-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesSkin Irrit. 2 (93.2%)

毒性情報

Treatment · 1 件

Gastric evacuation, either by the induction of emesis, lavage, or both, should be performed immediately. Maintenance of adequate ventilation is essential. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Fluids should be administered intravenously to maintain blood pressure and encourage diuresis. The value of dialysis in treatment of benzodiazepine overdose has not been determined. The physician may wish to consider contacting a Poison Control Center for up-to-date information on the management of hypnotic drug product overdose. Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. (L1712)

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein Binding93% protein bound, independant of concentration.
PharmacodynamicsEstazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Mechanism of Action · 1 件

Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Biological Half-LifeThe range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.
Metabolism/Metabolites · 3 件

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A).

Estazolam has known human metabolites that include 4-hydroxyestazolam.

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A). Route of Elimination: Estazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged. Half Life: The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.

関連反応

7 件
反応記録を作成
HRID 615852 の反応式
HRID 615852反応物として
HRID 615853 の反応式
HRID 615853反応物として
HRID 867066 の反応式
HRID 867066生成物として
HRID 1288066 の反応式
HRID 1288066生成物として
HRID 1764511 の反応式
HRID 1764511生成物として
HRID 1764512 の反応式
HRID 1764512生成物として
HRID 1764513 の反応式
HRID 1764513生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
29975-16-4
PubChem CID
3261
DTXSID
DTXSID5020572
ChEMBL
CHEMBL285674
ChEBI
CHEBI:4858
UNII
36S3EQV54C
EC Number
249-982-4
Nikkaji
J9.280K
228 · 228-229°
沸点
448.04 °C · 448.04°C (rough estimate)
比重(密度)
1.2294 · 1.2294 (rough estimate)
屈折率
1.611 · 1.6110 (estimate)
闪点
11 °C · 11 °C
貯蔵温度
2 · 2-8°C
溶解性
30 mg/ml; · DMF: 30 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml
外見
A crystalline solid
酸解離定数(Pka)
2.84 · pKa 2.84(H2O) (Uncertain)
CAS データベース
29975 · 29975-16-4(CAS DataBase Reference)
NISTの化学物質情報
Estazolam(29975-16-4)
Health Effects
May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1 件

Estazolam, as with other benzodiazepines, is rarely associated with serum ALT elevations, and clinically apparent liver injury from estazolam is extremely rare, if it occurs at all. There have been no published case reports of symptomatic, acute liver injury from estazolam. Isolated cases of clinically apparent hepatitis have been reported with other benzodiazepines including alprazolam, chlordiazepoxide, clonazepam, diazepam, flurazepam, lorazepam, and triazolam. The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic and mild-to-moderate in severity with a latency of 1 to 6 months and full recovery within 1 to 2 months. Fever and rash have not been described nor has autoantibody formation.

Exposure Routes · 1 件

Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.

Toxicity Summary · 1 件

Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Signs and SymptomsSymptoms of overdose include confusion, depressed breathing, drowsiness and eventually coma, lack of coordination, and slurred speech.
Carcinogen Classification · 6 件

Estazolam

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 66: (1996) Some Pharmaceutical Drugs

1996

1996

3, not classifiable as to its carcinogenicity to humans. (L135)

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Estazolam

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 2 件

◉ Summary of Use during Lactation

◈ What is estazolam?

Toxicity DataLD50: 740 mg/kg (oral, male mice) (L1867) LD50: 3200 mg/kg (oral, rat) (L1867) LD50 300 mg/kg (oral, rabbit) (L1867)

安全データ

wgk
3
rtecs
XZ5473500
ridadr
3249
毒性
LD50 orally in male mice, rats and rabbits: 740, 3200, 300 mg/kg (Yokotani)
hs_code
2933910000
risk_code
36/37/38-39/23/24/25-23/24/25-11
hazard_code
Xi,T,F
safety_code
36/37/39-45-36/37-16-7
hazard_class
6.1(b)
packing_group
III
FDA Pharmacological Classification · 6 件

36S3EQV54C

ESTAZOLAM

Established Pharmacologic Class [EPC] - Benzodiazepine

Chemical Structure [CS] - Benzodiazepines

Estazolam is a Benzodiazepine.

ESTAZOLAM

MeSH Pharmacological Classification · 3 件

Drugs used to prevent SEIZURES or reduce their severity.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Absorption, Distribution and Excretion · 2 件

Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.

Estazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged.

Tissue LocationsKidney
Cellular LocationsMembrane

用途と製造

UsesFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Use ClassificationPharmaceuticals

応用分野

用途ベンゾジアゼピン系化合物で す。GABA受容体に作用し、中枢神経抑制作 用を示します。作用時間は中時間です。

使用A benzodiazepine derivative possessing anxiolytic, anticonvulsant, and muscle relaxant properties. It is commonly prescribed to treat short-term insomnia. Controlled Substance.

上流・下流製品情報

上流原料

4-クロロニトロベンゼンphenylacetonitrileオルトぎ酸トリエチルクロロアセチルクロリドヘキサメチレンテトラミンホルモヒドラジドN′-(7-クロロ-5-フェニル-3H-1,4-ベンゾジアゼピン-2-イル)アセトヒドラジドN-desmethyl-N(4)-desoxychlordiazepoxideホルムアミジン塩酸塩
補足説明 · 1 件

定義ChEBI: A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term ma agement of insomnia.